These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11720452)

  • 1. Megestrol treatment in patients with hepatocellular carcinoma.
    Farinati F; Gianni S; De Giorgio M; Fiorentini S
    Br J Cancer; 2001 Nov; 85(10):1606-8. PubMed ID: 11720452
    [No Abstract]   [Full Text] [Related]  

  • 2. [Does anti-estrogen therapy after estrogen receptor analysis have value in palliative therapy of hepatocellular carcinoma?].
    Kreysel C; Porschen R
    Z Gastroenterol; 1998 Jul; 36(7):605-7. PubMed ID: 9738309
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study.
    Cappa FM; Cantarini MC; Magini G; Zambruni A; Bendini C; Santi V; Bernardi M; Trevisani F
    Dig Liver Dis; 2005 Apr; 37(4):254-9. PubMed ID: 15788209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors.
    Villa E; Ferretti I; Grottola A; Buttafoco P; Buono MG; Giannini F; Manno M; Bertani H; Dugani A; Manenti F
    Br J Cancer; 2001 Apr; 84(7):881-5. PubMed ID: 11286465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with inhibitors of angiogenesis in advanced hepatocellular carcinoma: a new tool in our hands or simply a hope?
    Cipriani G; Mazzanti R
    Dig Liver Dis; 2005 Apr; 37(4):230-1. PubMed ID: 15788205
    [No Abstract]   [Full Text] [Related]  

  • 6. Type of estrogen receptor determines response to antiestrogen therapy.
    Villa E; Dugani A; Fantoni E; Camellini L; Buttafoco P; Grottola A; Pompei G; De Santis M; Ferrari A; Manenti F
    Cancer Res; 1996 Sep; 56(17):3883-5. PubMed ID: 8752151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A therapeutic study of hepatocellular carcinoma using octreotide (HECTOR). Hepatocellular Carcinoma: Treatment with Octreotide].
    Allgaier HP; Becker G; Blum HE
    Dtsch Med Wochenschr; 2000 Mar; 125(11):320. PubMed ID: 10761474
    [No Abstract]   [Full Text] [Related]  

  • 8. Tamoxifen in hepatocellular carcinoma.
    Chow P; Kiat TC; Choo TB; Machin D
    Lancet; 1998 Sep; 352(9130):819-20. PubMed ID: 9737316
    [No Abstract]   [Full Text] [Related]  

  • 9. Complete, long-standing regression of hepatocellular carcinoma after somatostatin analogue treatment.
    Rahmi G; Malka D; Tomasic G; Dromain C; Ducreux M; Boige V
    J Clin Oncol; 2007 Jun; 25(16):e15-6. PubMed ID: 17538153
    [No Abstract]   [Full Text] [Related]  

  • 10. Octreotide and hepatocellular carcinoma.
    Farinati F; Sergio A; Baldan A; Zucchetta P; Corleto VD
    Br J Cancer; 2007 Jun; 96(11):1778-9. PubMed ID: 17505506
    [No Abstract]   [Full Text] [Related]  

  • 11. [Somatostatin analogue (octreotide)].
    Sano K; Makuuchi M
    Nihon Rinsho; 2001 Oct; 59 Suppl 6():674-7. PubMed ID: 11762035
    [No Abstract]   [Full Text] [Related]  

  • 12. Octreotide treatment of hepatocellular carcinoma.
    Kouroumalis E; Samonakis D; Skordilis P
    Hepatology; 2003 Feb; 37(2):477. PubMed ID: 12540801
    [No Abstract]   [Full Text] [Related]  

  • 13. [Regression of hepatocellular carcinoma under Tamoxifen: report of one case and review of the literature].
    Macaigne G; Auriault ML; Boivin JF; Cheaib S; Chayette C; Deplus R
    Gastroenterol Clin Biol; 2002 Dec; 26(12):1165-7. PubMed ID: 12520204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Investigating the alpha-1-fetoprotein in the blood stream of patients with primary hepatocellular carcinoma in the course of chemotherapy (author's transl)].
    Zizkovský V; Kordac V; Masek Z; Stĕpán J; Korcáková J; Blahníková L
    Cesk Gastroenterol Vyz; 1980 Oct; 34(7):465-73. PubMed ID: 6160917
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of hepatocellular carcinoma with tamoxifen].
    Raoul JL
    Gastroenterol Clin Biol; 1996 Mar; 20(2):221-2. PubMed ID: 8761695
    [No Abstract]   [Full Text] [Related]  

  • 16. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma.
    Vora SR; Zheng H; Stadler ZK; Fuchs CS; Zhu AX
    Oncologist; 2009 Jul; 14(7):717-25. PubMed ID: 19581525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen does not improve overall survival in people with advanced-stage hepatocellular carcinoma.
    Chow PK
    Cancer Treat Rev; 2005 Oct; 31(6):491-5. PubMed ID: 16214294
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide.
    Rabe C; Pilz T; Allgaier HP; Halm U; Strasser C; Wettstein M; Sauerbruch T; Caselmann WH
    Z Gastroenterol; 2002 Jun; 40(6):395-400. PubMed ID: 12055662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tamoxifen and hepatocellular carcinoma: verdict after enthusiasm...].
    Barbare JC
    Gastroenterol Clin Biol; 1996; 20(6-7):609-10. PubMed ID: 8881581
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical significance of alpha-fetoprotein: involvement in proliferation, angiogenesis, and apoptosis of hepatocellular carcinoma.
    Mitsuhashi N; Kobayashi S; Doki T; Kimura F; Shimizu H; Yoshidome H; Ohtsuka M; Kato A; Yoshitomi H; Nozawa S; Furukawa K; Takeuchi D; Suda K; Miura S; Miyazaki M
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e189-97. PubMed ID: 18466288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.